Eric Fry sees upside on Wegovy pill demand, while Zacks expects 2026 revenue and EPS to fall. The FDA call on CagriSema is expected in Q4 2026.
Recap by typeshit. Full story at AD HOC NEWS.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
He describes tirzepatide acting on appetite hormones and cites a 72-week trial where adults without diabetes lost an average 15% to 21% of weight, depending on dose.
A 10-part thread from Dr. Rafi on planning past the first month of weight loss injections, since he notes the weight can come back after stopping.
Loading…